Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018562
Filing Date
2023-11-09
Accepted
2023-11-09 16:05:51
Documents
70
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rain-20230930x10q.htm   iXBRL 10-Q 1549302
2 EX-10.1 rain-20230930xex10d1.htm EX-10.1 19563
3 EX-10.2 rain-20230930xex10d2.htm EX-10.2 69879
4 EX-31.1 rain-20230930xex31d1.htm EX-31.1 13754
5 EX-31.2 rain-20230930xex31d2.htm EX-31.2 17833
6 EX-32.1 rain-20230930xex32d1.htm EX-32.1 12778
  Complete submission text file 0001558370-23-018562.txt   7070239

Data Files

Seq Description Document Type Size
7 EX-101.SCH rain-20230930.xsd EX-101.SCH 48384
8 EX-101.CAL rain-20230930_cal.xml EX-101.CAL 54168
9 EX-101.DEF rain-20230930_def.xml EX-101.DEF 162348
10 EX-101.LAB rain-20230930_lab.xml EX-101.LAB 470825
11 EX-101.PRE rain-20230930_pre.xml EX-101.PRE 324107
64 EXTRACTED XBRL INSTANCE DOCUMENT rain-20230930x10q_htm.xml XML 1315067
Mailing Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560
Business Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560 (510) 953-5559
Rain Oncology Inc. (Filer) CIK: 0001724979 (see all company filings)

EIN.: 821130967 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40356 | Film No.: 231392306
SIC: 2834 Pharmaceutical Preparations